Last reviewed · How we verify
T101 Group
At a glance
| Generic name | T101 Group |
|---|---|
| Sponsor | Tasly Tianjin Biopharmaceutical Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- IB-T101 Injection for Treatment of Patients with Advanced Clear Cell Renal Cell Carcinoma (PHASE1)
- Validation of TERA Bio Station T101 of COVID-19 Tested Population.
- Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) in Chronic Hepatitis B Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- T101 Group CI brief — competitive landscape report
- T101 Group updates RSS · CI watch RSS
- Tasly Tianjin Biopharmaceutical Co., Ltd. portfolio CI